Zydus Cadila gets final nod from USFDA for Fulvestrant injection

The drug will be manufactured at the group’s formulation manufacturing facility at the Zydus Biologics, Ahmedabad

97
USFDA
Picture: Pixabay

Last Updated on August 2, 2021 by The Health Master

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Fulvestrant injection, 250 mg/5 mL per Single-Dose Pre-filled Syringe (USRLD: Faslodex injection), a statement from Zydus said.

It also said that the (50 mg/mL) Fulvestrant injection is used alone, or in combination with other drugs to treat a certain type of hormone receptor positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in women who have experienced menopause.

The drug will be manufactured at the group’s formulation manufacturing facility at the Zydus Biologics, Ahmedabad, the statement added.

USFDA inspection ends with ‘Zero’ observations: Alkem

Granules Pharma clears USFDA audit

Zydus Cadila gets USFDA nod for Ibrutinib tablets

Lupin gets USFDA nod for generic Antifungal drug

Unichem gets tentative USFDA nod for drug to treat Diabetes

Alembic gets USFDA final nod for Erlotinib Tablets

CDSCO to regulate Cosmetic products like skin patches

Quality Medical Devices with low manufacturing cost a challenge

Rs 6 lakh per bottle in India: Roche launches spinal treatment…

USFDA inspection ends with ‘Zero’ observations: Alkem

NPPA fixes ceiling prices of 355 Medicines and 882 Formulations

Pharmexcil seeks list of products from Pharma Exporters

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner